Skip to content

A clinical trial to study the role of ketamine mouthwash for the treatment of severe oral mucositis pain in children with cancer

Ketamine Mouthwash versus Placebo in the Treatment of Severe Oral Mucositis Pain in Children with Cancer: A Randomized Double-blind Placebo-controlled Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015499
Enrollment
44
Registered
2018-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T451- Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs

Interventions

Intervention1: Ketamine Mouthwash: Ketamine mouthwash (prepared as 4 mg of ketamine in 1 ml solution, prepared by diluting marketed iv formulation of ketamine in appropriate pharmaceutical diluent) in

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of 8-18 years of age 2. Received at least 1 dose of cancer chemotherapy 3. Have severe oral mucositis (grade 3 or grade 4 according to WHO Oral Mucositis Grading scale) 4. Have an oral mucositis pain score of 2 or more on Wong Baker faces pain rating scale (0-5)

Exclusion criteria

Exclusion criteria: 1. Have taken a systemic analgesic (such as paracetamol or tramadol) within last 4 hours, or applied topical local anaesthetic (such as lignocaine or xylocaine) to the oral cavity within last 1-hour, of the time of randomisation of the patient in the study groups 2. Received prior ketamine dose within 48 hours of enrolment (by any route) 3. Any contra-indications to the use of ketamine: i. Any documented hypersensitivity to ketamine ii. Signs and symptoms of raised intra cranial pressure iii. Blood pressure above 95th centile for age and height, at least 2 readings 15 minutes apart

Design outcomes

Primary

MeasureTime frame
Mean reduction of oral mucositis pain (on a numeric 6-point scale) after administration of ketamine mouthwash as compared to placeboTimepoint: At 1 hour after administration of mouthwash (ketamine/ placebo)

Secondary

MeasureTime frame
Analgesic agent required at 1 hour of administration of mouthwash (ketamine/ placebo) with doseTimepoint: At 1 hour after administration of mouthwash (ketamine/ placebo);Occurrence of adverse effects of topical ketamine (Sedation, nausea, vomiting, hallucinations, excessive salivation, vertigo, ataxia, any other)Timepoint: Till 4 hours after administration of mouthwash (ketamine/ placebo);Time duration for which the pain reduction effect, if any, lastedTimepoint: Till 4 hours after administration of mouthwash (ketamine/ placebo);Time of onset of oral mucositis pain reduction, if any.Timepoint: Till 4 hours after administration of mouthwash (ketamine/ placebo)

Countries

India

Contacts

Public ContactSatya Prakash

All India Institute of Medical Sciences, New Delhi

satyaprakash1994@gmail.com9958980242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026